{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:03:06Z","timestamp":1779174186158,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00520-023-07965-3","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:01:40Z","timestamp":1690588900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Yunxia","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingge","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"key":"7965_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115\u2013132. https:\/\/doi.org\/10.3322\/caac.21338","journal-title":"CA Cancer J Clin"},{"key":"7965_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/cm9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 135:584\u2013590. https:\/\/doi.org\/10.1097\/cm9.0000000000002108","journal-title":"Chin Med J"},{"key":"7965_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1056\/NEJMra1703413","volume":"377","author":"M Reck","year":"2017","unstructured":"Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377:849\u2013861. https:\/\/doi.org\/10.1056\/NEJMra1703413","journal-title":"N Engl J Med"},{"key":"7965_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9\u201329. https:\/\/doi.org\/10.3322\/caac.21208","journal-title":"CA Cancer J Clin"},{"key":"7965_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","volume":"135","author":"K Nosaki","year":"2019","unstructured":"Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G (2019) Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 135:188\u2013195. https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.004","journal-title":"Lung Cancer"},{"key":"7965_CR6","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/jco.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol 39:2339\u20132349. https:\/\/doi.org\/10.1200\/jco.21.00174","journal-title":"J Clin Oncol"},{"key":"7965_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(16)32517-x","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x","journal-title":"Lancet"},{"key":"7965_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"7965_CR9","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/cam4.2940","volume":"9","author":"K Ala-Leppilampi","year":"2020","unstructured":"Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, Abdul Razak AR, Joshua AM, Hogg D, Bedard PL, Leighl N, Oza AM, Parsons JA, Hansen AR (2020) Cancer patients\u2019 experiences with immune checkpoint modulators: a qualitative study. Cancer Med 9:3015\u20133022. https:\/\/doi.org\/10.1002\/cam4.2940","journal-title":"Cancer Med"},{"key":"7965_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s12885-020-07215-3","volume":"20","author":"L Jamieson","year":"2020","unstructured":"Jamieson L, Forster MD, Zaki K, Mithra S, Alli H, O\u2019Connor A, Patel A, Wong ICK, Chambers P (2020) Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study. BMC Cancer 20:743. https:\/\/doi.org\/10.1186\/s12885-020-07215-3","journal-title":"BMC Cancer"},{"key":"7965_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11764-020-00853-3","volume":"14","author":"R Park","year":"2020","unstructured":"Park R, Shaw JW, Korn A, McAuliffe J (2020) The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. J Cancer Surviv 14:363\u2013376. https:\/\/doi.org\/10.1007\/s11764-020-00853-3","journal-title":"J Cancer Surviv"},{"key":"7965_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2217\/imt-2019-0071","volume":"11","author":"E Rassy","year":"2019","unstructured":"Rassy E, Mezquita L, Remon J, Besse B (2019) Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors? Immunotherapy 11:1149\u20131160. https:\/\/doi.org\/10.2217\/imt-2019-0071","journal-title":"Immunotherapy"},{"key":"7965_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00262-019-02310-2","volume":"68","author":"E Nadal","year":"2019","unstructured":"Nadal E, Massuti B, D\u00f3mine M, Garc\u00eda-Campelo R, Cobo M, Felip E (2019) Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 68:341\u2013352. https:\/\/doi.org\/10.1007\/s00262-019-02310-2","journal-title":"Cancer Immunol Immunother"},{"key":"7965_CR14","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/jco.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlh\u00e4eufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924\u20133933. https:\/\/doi.org\/10.1200\/jco.2017.74.3062","journal-title":"J Clin Oncol"},{"key":"7965_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1200\/jco.19.02446","volume":"38","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P (2020) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013positive, advanced non\u2013small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 38:1580\u20131590. https:\/\/doi.org\/10.1200\/jco.19.02446","journal-title":"J Clin Oncol"},{"key":"7965_CR16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/s1470-2045(19)30519-4","volume":"20","author":"R Hui","year":"2019","unstructured":"Hui R, \u00d6zg\u00fcro\u011flu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Ryd\u00e9n A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ (2019) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 20:1670\u20131680. https:\/\/doi.org\/10.1016\/s1470-2045(19)30519-4","journal-title":"Lancet Oncol"},{"key":"7965_CR17","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1634\/theoncologist.2019-IO-S1-s02","volume":"24","author":"S Lu","year":"2019","unstructured":"Lu S, Yu Y, Yang Y (2019) Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors. Oncologist 24:S21\u2013s30. https:\/\/doi.org\/10.1634\/theoncologist.2019-IO-S1-s02","journal-title":"Oncologist"},{"key":"7965_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/104973239900900609","volume":"9","author":"C Thompson","year":"1999","unstructured":"Thompson C (1999) Qualitative research into nurse decision making: factors for consideration in theoretical sampling. Qual Health Res 9:815\u2013828. https:\/\/doi.org\/10.1177\/104973239900900609","journal-title":"Qual Health Res"},{"key":"7965_CR19","first-page":"1189","volume":"34","author":"MQ Patton","year":"1999","unstructured":"Patton MQ (1999) Enhancing the quality and credibility of qualitative analysis. Health Serv Res 34:1189\u20131208","journal-title":"Health Serv Res"},{"key":"7965_CR20","first-page":"60","volume":"72","author":"M Luciani","year":"2019","unstructured":"Luciani M, Jack SM, Campbell K, Orr E, Durepos P, Li L, Strachan P, Di Mauro S (2019) An introduction to qualitative health research. Prof Inferm 72:60\u201368","journal-title":"Prof Inferm"},{"key":"7965_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/medu.14380","volume":"55","author":"J Thompson Burdine","year":"2021","unstructured":"Thompson Burdine J, Thorne S, Sandhu G (2021) Interpretive description: a flexible qualitative methodology for medical education research. Med Educ 55:336\u2013343. https:\/\/doi.org\/10.1111\/medu.14380","journal-title":"Med Educ"},{"key":"7965_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1049732310392595","volume":"21","author":"S Thorne","year":"2011","unstructured":"Thorne S (2011) Toward methodological emancipation in applied health research. Qual Health Res 21:443\u2013453. https:\/\/doi.org\/10.1177\/1049732310392595","journal-title":"Qual Health Res"},{"key":"7965_CR23","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s00432-020-03336-1","volume":"146","author":"A Ihrig","year":"2020","unstructured":"Ihrig A, Richter J, Gr\u00fcllich C, Apostolidis L, Horak P, Villalobos M, Grapp M, Friederich HC, Maatouk I (2020) Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. J Cancer Res Clin Oncol 146:3189\u20133198. https:\/\/doi.org\/10.1007\/s00432-020-03336-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"7965_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","volume":"22","author":"TF Nishijima","year":"2017","unstructured":"Nishijima TF, Shachar SS, Nyrop KA, Muss HB (2017) Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 22:470\u2013479. https:\/\/doi.org\/10.1634\/theoncologist.2016-0419","journal-title":"Oncologist"},{"key":"7965_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-020-0707-5","volume":"21","author":"MSY Thong","year":"2020","unstructured":"Thong MSY, van Noorden CJF, Steindorf K, Arndt V (2020) Cancer-related fatigue: causes and current treatment options. Curr Treat Options Oncol 21:17. https:\/\/doi.org\/10.1007\/s11864-020-0707-5","journal-title":"Curr Treat Options Oncol"},{"key":"7965_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","volume":"31","author":"DE Magee","year":"2020","unstructured":"Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, Kulkarni GS (2020) Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol\u202f: Offic J\u00a0Europe Soc Med Oncol 31:50\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.008","journal-title":"Ann Oncol : Offic J\u00a0Europe Soc Med Oncol"},{"key":"7965_CR27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1001\/jamaoto.2020.1798","volume":"146","author":"S Marcus","year":"2020","unstructured":"Marcus S (2020) Immunotherapy. JAMA Otolaryngology. Head Neck Surg 146:988. https:\/\/doi.org\/10.1001\/jamaoto.2020.1798","journal-title":"Head Neck Surg"},{"key":"7965_CR28","doi-asserted-by":"publisher","unstructured":"Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM, Van Boemmel-Wegmann S, Lo-Ciganic WH (2020) Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis. JAMA network open 3:e201611. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.1611","DOI":"10.1001\/jamanetworkopen.2020.1611"},{"key":"7965_CR29","doi-asserted-by":"publisher","first-page":"e1190","DOI":"10.1634\/theoncologist.2018-0820","volume":"24","author":"A Wong","year":"2019","unstructured":"Wong A, Billett A, Milne D (2019) Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy? Oncologist 24:e1190\u2013e1196. https:\/\/doi.org\/10.1634\/theoncologist.2018-0820","journal-title":"Oncologist"},{"key":"7965_CR30","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00520-017-3621-z","volume":"25","author":"E Shuk","year":"2017","unstructured":"Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R et al (2017) Patient perspectives on ipilimumab across the melanoma treatment trajectory. Support Care Cancer 25:2155\u20132167. https:\/\/doi.org\/10.1007\/s00520-017-3621-z","journal-title":"Support Care Cancer"},{"key":"7965_CR31","doi-asserted-by":"publisher","first-page":"e2090","DOI":"10.1002\/onco.13945","volume":"26","author":"LA Petrillo","year":"2021","unstructured":"Petrillo LA, Zhou AZ, Sullivan R, Volandes A, Greer JA, Temel JS, El-Jawahri A (2021) Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced cancer. Oncologist 26:e2090\u2013e2093. https:\/\/doi.org\/10.1002\/onco.13945","journal-title":"Oncologist"},{"key":"7965_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"key":"7965_CR33","doi-asserted-by":"publisher","unstructured":"Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP, Mathew N, Garje R, Chandra AB (2022) Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10040790","DOI":"10.3390\/biomedicines10040790"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07965-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:17:26Z","timestamp":1691727446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07965-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7965"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07965-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2571647\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board at the Tianjin Medical University Cancer Institute & Hospital. This study was performed in line with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was approved by the institutional review board at the Tianjin Medical University Cancer Institute & Hospital (Approval No. bc2022158), and informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participant has consented to the submission of their quotes to the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"498"}}